Ben Hindson

Ben Hindson has served as Chief Scientific Officer and Director of 10x Genomics since its founding in 2012. Prior to 10x Genomics, he was Co-founder and Chief Scientific Officer of Quantalife, a privately-held life sciences company that developed and commercialized a droplet digital PCR platform, until its sale to Bio-Rad Laboratories in 2011. Before QuantaLife, Ben served in various positions of increasing responsibility at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Nonproliferation Program. He has published extensively in his field and holds numerous patents for assays and instrumentation. Ben earned his B.S. in Chemistry and his Ph.D in Chemistry from Deakin University, Australia.